| Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1–positive acute … I Iacobucci, CT Storlazzi, D Cilloni, A Lonetti, E Ottaviani, S Soverini, ... Blood, The Journal of the American Society of Hematology 114 (10), 2159-2167, 2009 | 270 | 2009 |
| Identification of an evolutionarily conserved family of inorganic polyphosphate endopolyphosphatases A Lonetti, Z Szijgyarto, D Bosch, O Loss, C Azevedo, A Saiardi Journal of Biological Chemistry 286 (37), 31966-31974, 2011 | 239 | 2011 |
| Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting F Chiarini, A Lonetti, C Evangelisti, F Buontempo, E Orsini, C Evangelisti, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (3), 449-463, 2016 | 170 | 2016 |
| Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new … I Iacobucci, A Lonetti, F Messa, D Cilloni, F Arruga, E Ottaviani, S Paolini, ... Blood, The Journal of the American Society of Hematology 112 (9), 3847-3855, 2008 | 150 | 2008 |
| Autophagy in acute leukemias: a double-edged sword with important therapeutic implications C Evangelisti, C Evangelisti, F Chiarini, A Lonetti, F Buontempo, LM Neri, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1853 (1), 14-26, 2015 | 117 | 2015 |
| Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis S Soverini, A Vitale, A Poerio, A Gnani, S Colarossi, I Iacobucci, G Cimino, ... Haematologica 96 (4), 552, 2011 | 109 | 2011 |
| IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia I Iacobucci, N Iraci, M Messina, A Lonetti, S Chiaretti, E Valli, A Ferrari, ... PloS one 7 (7), e40934, 2012 | 105 | 2012 |
| Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling F Buontempo, E Orsini, LR Martins, I Antunes, A Lonetti, F Chiarini, ... Leukemia 28 (3), 543-553, 2014 | 93 | 2014 |
| CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients I Iacobucci, A Ferrari, A Lonetti, C Papayannidis, F Paoloni, S Trino, ... Clinical cancer research 17 (23), 7413-7423, 2011 | 88 | 2011 |
| Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia A Lonetti, IL Antunes, F Chiarini, E Orsini, F Buontempo, F Ricci, ... Leukemia 28 (6), 1196-1206, 2014 | 86 | 2014 |
| A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia I Iacobucci, M Sazzini, P Garagnani, A Ferrari, A Boattini, A Lonetti, ... Leukemia research 35 (8), 1052-1059, 2011 | 86 | 2011 |
| Therapeutic targeting of CK2 in acute and chronic leukemias F Buontempo, JA McCubrey, E Orsini, M Ruzzene, A Cappellini, A Lonetti, ... Leukemia 32 (1), 1-10, 2018 | 84 | 2018 |
| Targeted therapies for pediatric AML: gaps and perspective A Lonetti, A Pession, R Masetti Frontiers in pediatrics 7, 463, 2019 | 79 | 2019 |
| Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments I Iacobucci, C Papayannidis, A Lonetti, A Ferrari, M Baccarani, G Martinelli Current hematologic malignancy reports 7, 133-143, 2012 | 78 | 2012 |
| A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia F Chiarini, A Lonetti, G Teti, E Orsini, D Bressanin, A Cappellini, F Ricci, ... Oncotarget 3 (12), 1615, 2012 | 67 | 2012 |
| The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia … I Iacobucci, A Lonetti, F Paoloni, C Papayannidis, A Ferrari, CT Storlazzi, ... Haematologica 95 (10), 1683, 2010 | 67 | 2010 |
| Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway A Lonetti, A Cappellini, A Bertaina, F Locatelli, A Pession, F Buontempo, ... Journal of Hematology & Oncology 9, 1-16, 2016 | 62 | 2016 |
| c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cells T Waldron, M De Dominici, AR Soliera, A Audia, I Iacobucci, A Lonetti, ... Leukemia 26 (4), 644-653, 2012 | 51 | 2012 |
| Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro … F Buontempo, E Orsini, A Lonetti, A Cappellini, F Chiarini, C Evangelisti, ... Oncotarget 7 (2), 1323, 2016 | 50 | 2016 |
| Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia AM Spartà, D Bressanin, F Chiarini, A Lonetti, A Cappellini, C Evangelisti, ... Cell Cycle 13 (14), 2237-2247, 2014 | 45 | 2014 |
Giovanni MartinelliProfessor of Hematology "L. e A. Seragnoli" InstituteVerified email at unibo.it
